New York State Teachers Retirement System Purchases New Shares in ADMA Biologics, Inc. (NASDAQ:ADMA)

New York State Teachers Retirement System bought a new position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 91,114 shares of the biotechnology company's stock, valued at approximately $1,821,000.

Several other institutional investors and hedge funds have also recently modified their holdings of ADMA. Quest Partners LLC purchased a new stake in shares of ADMA Biologics during the 2nd quarter valued at $29,000. EntryPoint Capital LLC purchased a new stake in ADMA Biologics during the first quarter valued at about $31,000. USA Financial Formulas lifted its stake in ADMA Biologics by 8.6% during the third quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company's stock worth $136,000 after purchasing an additional 539 shares during the last quarter. CWM LLC boosted its holdings in shares of ADMA Biologics by 114.2% in the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company's stock worth $92,000 after purchasing an additional 4,367 shares in the last quarter. Finally, Acadian Asset Management LLC bought a new position in shares of ADMA Biologics during the 2nd quarter valued at about $93,000. Hedge funds and other institutional investors own 75.68% of the company's stock.

ADMA Biologics Trading Up 14.7 %

Shares of ADMA Biologics stock traded up $2.90 on Friday, hitting $22.62. The stock had a trading volume of 9,717,443 shares, compared to its average volume of 4,993,041. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74. ADMA Biologics, Inc. has a one year low of $3.60 and a one year high of $23.52. The stock's 50-day simple moving average is $18.12 and its two-hundred day simple moving average is $13.89. The stock has a market cap of $5.27 billion, a price-to-earnings ratio of 161.57 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.08 by $0.05. The business had revenue of $107.20 million for the quarter, compared to analyst estimates of $86.44 million. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The company's revenue was up 78.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.02) EPS. As a group, sell-side analysts predict that ADMA Biologics, Inc. will post 0.49 EPS for the current year.

Insider Buying and Selling

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the company's stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the transaction, the director now owns 153,941 shares of the company's stock, valued at $2,843,290.27. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, Director Lawrence P. Guiheen sold 9,000 shares of ADMA Biologics stock in a transaction on Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the sale, the director now owns 153,941 shares in the company, valued at $2,843,290.27. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Adam S. Grossman sold 236,889 shares of the business's stock in a transaction on Monday, August 26th. The shares were sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the transaction, the chief executive officer now directly owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 466,900 shares of company stock valued at $8,224,121 over the last ninety days. 3.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ADMA. Raymond James boosted their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research report on Friday. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $20.00 price objective on shares of ADMA Biologics in a research note on Friday, September 20th. Finally, HC Wainwright lifted their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a research report on Friday. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $21.25.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.